Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Total Current Liabilities (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Total Current Liabilities data on record, last reported at $24.5 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 38.07% year-over-year to $24.5 million; the TTM value through Dec 2025 reached $24.5 million, down 38.07%, while the annual FY2025 figure was $24.5 million, 38.07% down from the prior year.
  • Total Current Liabilities reached $24.5 million in Q4 2025 per TRDA's latest filing, up from $24.0 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $173.9 million in Q1 2024 and bottomed at $15.4 million in Q1 2022.
  • Average Total Current Liabilities over 4 years is $70.7 million, with a median of $32.0 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: surged 856.79% in 2023, then tumbled 89.4% in 2025.
  • A 4-year view of Total Current Liabilities shows it stood at $22.0 million in 2022, then soared by 622.72% to $158.8 million in 2023, then plummeted by 75.14% to $39.5 million in 2024, then tumbled by 38.07% to $24.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $24.5 million in Q4 2025, $24.0 million in Q3 2025, and $19.8 million in Q2 2025.